Chinese inhibitor drug candidate becomes first to enter phase
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles
'The Apprentice,' about a young Donald Trump, premieres in Cannes
CANNES, France (AP) — While Donald Trump’s hush money trial entered its sixth week in New York, an o2024-05-21Promotion Event for Liangma River Held in Beijing
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Crackdown Targets Women, Child Trafficking
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21S. Korea's opposition party overwhelmingly leads exit polls in parliamentary elections
South Korea's main liberal opposition Democratic Party overwhelmingly led exit polls in parliame2024-05-21- WikiLeaks founder Julian Assange's five-year battle against extradition to the US for espionage char2024-05-21
Young Entrepreneur Develops Persimmon Businesses, Helps Rural Women Increase Incomes
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
atest comment